Stock Events

Cabaletta Bio 

$10.66
23
-$1.9-15.13% Friday 20:00

Statistics

Day High
13.5
Day Low
10
52W High
26.35
52W Low
9.52
Volume
4,729,625
Avg. Volume
952,281
Mkt Cap
514.63M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

15MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.51
-0.17
0.18
0.52
Expected EPS
-0.44
Actual EPS
-0.51

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CABA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.91B
CRISPR Therapeutics is involved in gene editing, a technology that can be applied to the development of treatments for autoimmune diseases, directly competing with Cabaletta Bio's focus on engineered T cell therapies.
Intellia Therapeutics
NTLA
Mkt Cap2.19B
Intellia Therapeutics is a leading developer of CRISPR gene editing therapies, potentially targeting similar autoimmune and other diseases as Cabaletta Bio.
Editas Medicine
EDIT
Mkt Cap435.86M
Editas Medicine operates in the CRISPR gene editing space, focusing on delivering transformative genetic treatments that could overlap with Cabaletta Bio's therapeutic areas.
Allogene Therapeutics
ALLO
Mkt Cap396.38M
Allogene Therapeutics focuses on allogeneic CAR T cell therapies, which could be used in similar applications to Cabaletta Bio's autologous T cell therapies, making them direct competitors.
Adaptimmune Therapeutics
ADAP
Mkt Cap157.75M
Adaptimmune Therapeutics specializes in T-cell receptor (TCR) engineered T cell therapies for cancer, but its technology could be adapted to target autoimmune diseases, competing with Cabaletta Bio.
Bluebird bio
BLUE
Mkt Cap98.95M
bluebird bio's gene therapy approach, including its work in CAR T and TCR therapies, positions it as a competitor in the advanced therapy medicinal products (ATMPs) space, including potential overlaps with Cabaletta's focus areas.
Fate Therapeutics
FATE
Mkt Cap418.9M
Fate Therapeutics is developing programmed cellular immunotherapies, including NK and T-cell therapies, which could compete with Cabaletta Bio's engineered T cell approaches for autoimmune diseases.
Sangamo Therapeutics
SGMO
Mkt Cap119.17M
Sangamo Therapeutics' gene editing technology, including zinc finger nuclease (ZFN) technology, targets genetic conditions that could overlap with Cabaletta Bio's therapeutic areas, making them competitors.
Biomarin Pharmaceutical
BMRN
Mkt Cap15.32B
BioMarin Pharmaceutical focuses on enzyme replacement therapies but is expanding into gene therapies, which could potentially compete with Cabaletta Bio's approach to treating autoimmune diseases.
Pfizer
PFE
Mkt Cap161.95B
Pfizer, with its broad interest in biopharmaceuticals, including investments in gene therapy and immunology, represents a potential competitor across multiple areas of Cabaletta Bio's interest due to its scale and breadth of research.

Analyst Ratings

36.2$Average Price Target
The highest estimate is $50.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Health Technology
Biotechnology
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Show more...
CEO
Employees
118
Country
US
ISIN
US12674W1099

Listings